6-dibenzothiophene-4-ylpyridine-3-ylamine | 1357165-77-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 6-dibenzothiophene-4-ylpyridine-3-ylamine
• 英文别名: 4-(5'-amino-2'-pyridyl)dibenzothiophene；6-dibenzothiophen-4-ylpyridin-3-ylamine；6-Dibenzothiophen-4-ylpyridin-3-amine
• CAS: 1357165-77-5
• 化学式: C₁₇H₁₂N₂S
• 分子量: 276.362
• InChiKey: JQMDMVLSLHFUGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  五羰基铁 、 6-dibenzothiophene-4-ylpyridine-3-ylamine 以 四氢呋喃 为溶剂， 反应 11.0h， 以68%的产率得到[{Fe(μ-m-apyBPT-κ³N,C,S)(CO)₂}Fe(CO)₃]
  参考文献：
  名称：

  Di- and Mononuclear Iron Complexes of N,C,S-Tridentate Ligands Containing an Aminopyridyl Group: Effect of the Pendant Amine Site on Catalytic Properties for Proton Reduction

  摘要：

  A series of diiron complexes of N,C,S-tridentate ligands containing a 6-, 5-, or 4-amino-2-pyridyl group, [{Fe(mu-L-kappa N-3,C,S)(CO)(2)}Fe(CO)(3)] (2, L = o-apyBPT; 3, L = m-apyBPT; 4, L = p-apyBPT), was synthesized: apyBPT is a doubly deprotonated form of 3'-(amino-2"-pyridyl)-1,1'bipheny1-2-thiol. Complexes 2-4 were converted to the mononuclear iron(II) complexes trans-[Fe(L-kappa(3) N,C,S)(CO)-(PMe2Ph)(2)] (6, L = o-apyBPT; 7, L = m-apyBPT; 8, L = p-apyBPT). In 2 and 6, the o-amino group is close to Fe bound to the aminopyridyl group. Cyclic voltammograms of 2-4 exhibit two consecutive one-electron reduction events, and catalytic current for proton reduction appears in the presence of acetic acid. The reduction potentials of 2-4 are similar to each other, while the overpotential for proton reduction with o-amino complex 2 is ca. 0.2 V lower than those with 3 and 4. In the mononuclear complexes 6-8, the redox potentials for the Fe-III/Fe-II couple are dependent on the position of the amino group in the pyridine ring, which is described by electronic and steric effects of the amino group. Such effects on the redox potentials are suppressed in the diiron complexes because the reduction occurs at the diiron core with g-accepting CO ligands, which is supported by DFT calculations. The lower overpotential in 2 compared with 3 and 4 is attributed to the concerted effect of the amino group proximal to the iron center. The amino group probably acts as a proton acceptor and assists the formation of the H-H bond from a hydride on the iron centers and a proton bound to the amino group.

  DOI：

  10.1021/acs.organomet.5b00366
• 作为产物：
  描述：

  2-氯-5-硝基吡啶 在 四(三苯基膦)钯 、 铁粉 、 氯化铵 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 反应 7.33h， 生成 6-dibenzothiophene-4-ylpyridine-3-ylamine
  参考文献：
  名称：

  MEDICINAL COMPOSITION IMPROVING LEPTIN RESISTANCE

  摘要：

  公开号：

  EP3042658B1

文献信息

• Naphthalene Derivative
  申请人：Kakizuka Akira

  公开号：US20130184241A1

  公开（公告）日：2013-07-18

  The present invention provides compounds which can regulate VCP activity. The present invention provides the compound of formula (I) (R is as defined in the description) or oxides, esters, prodrugs, pharmaceutically acceptable salts or solvates thereof. The compounds can regulate VCP activity, and thus are useful for treating VCP-mediated diseases such as neurodegenerative diseases.

  本发明提供了可以调节VCP活性的化合物。本发明提供了式(I)的化合物（其中R如描述中所定义）或其氧化物、酯、前药、药学上可接受的盐或溶剂。这些化合物可以调节VCP活性，因此可用于治疗VCP介导的疾病，如神经退行性疾病。
• NAPHTHALENE DERIVATIVE
  申请人：Daito Chemix Corporation

  公开号：EP2599771B1

  公开（公告）日：2016-09-14
• Medicinal Composition Improving Leptin Resistance
  申请人：KYOTO UNIVERSITY

  公开号：US20160303144A1

  公开（公告）日：2016-10-20

  The present invention provides a compound of formula (I) which improves leptin resistance, a pharmaceutical composition comprising the compound, a method for manufacturing a pharmaceutical for improving leptin resistance comprising using the compound, use of the compound for manufacturing a pharmaceutical for improving leptin resistance, and a method for improving leptin resistance comprising administering the compound or the pharmaceutical composition. The improvement of leptin resistance can lead treatment and/or prevention of a disorder associated with leptin resistance, including, particularly, metabolic disorder, obesity, hyperphagia, steatosis, diabetes, and dyslipidemia.
• US9573887B2
  申请人：——

  公开号：US9573887B2

  公开（公告）日：2017-02-21
• US9931351B2
  申请人：——

  公开号：US9931351B2

  公开（公告）日：2018-04-03